New 'Gene-Silencing' drug enters first human tests for fatal lung disease
Disease control
Recruiting now
This is a very early study to check the safety of a new drug called SRN001, which is being developed to treat a serious lung scarring disease called idiopathic pulmonary fibrosis. The study will give the drug to 30 healthy Korean and Caucasian men to see how their bodies react to…
Phase: PHASE1 • Sponsor: siRNAgen Therapeutics Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC